A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC

By sjmartinez • February 25, 2025

Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K. A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC. Future Oncol. 2025 Feb 24:1-13. doi: 10.1080/14796694.2025.2463880. Epub ahead of print. PMID: 39995095.

Tags: Hematology/Oncology, Publications

A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer

Finn RS, Rugo HS, Cortes J, Loibl S, Foley G, Gauthier E, Wang Y, Kim S, Anders L, Slamon DJ. A Decade After Approval of[...]

Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]

Garassino MC, Gadgeel S, Novello S, Halmos B, Felip E, Speranza G, Hui R, Garon EB, Horinouchi H, Sugawara S, Rodriguez-Abreu D, Reck M, Cristescu[...]

Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung cancer

Chan AA, Sankar K, Reckamp KL, Díaz B, Lee DJ. Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung[...]